Clinical trial
Use of CXCL9 as a Biomarker of Acthar Efficacy
NCT02523092 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Use of CXCL9 as a Biomarker of Acthar Efficacy
- Lead sponsor
- University of California, San Francisco
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- November 3, 2022
- Completion date
- January 31, 2025
- Enrollment
- 2 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.